Printer Friendly

US Drug Developers Antegrin, Cascadia Merge to Form Indalo Therapeutics.

MANews-(C)2009-2016

19 October 2016 - St. Louis, Missouri-based drug discovery and development company Antegrin Therapeutics has merged with Seattle, Washington-based drug company Cascadia Therapeutics to form novel therapy biotechnology company Indalo Therapeutics, the company said.

Financial terms of the deal were not disclosed.

The new organisation unites Antegrin's portfolio of small-molecule integrin antagonists with the drug-development expertise, seasoned executive experience, and track record of Cascadia.

Indalo Therapeutics is a biotechnology company dedicated to developing novel treatments for fibrotic diseases.

The company was founded to exploit the therapeutic potential of RGD-binding integrin antagonists by leveraging groundbreaking discoveries on the role of these integrins in the pathogenesis of fibrosis.

Its portfolio of integrin antagonists has potential utility in a broad range of fibrotic diseases. The company has received funding from BioGenerator, Missouri Technology Corp.,iSelect Fund, and other investors.

Antegrin Therapeutics, a drug discovery and development company, develops therapies and compounds for fibrotic diseases. The company was founded in 2014.

Country: USA

Sector: Biotechnology

Target: Antegrin Therapeutics

Buyer: Cascadia Therapeutics

Vendor:

Deal size in USD:

Type: Merger

Financing:

Status: Closed

Buyer advisor: , ,

Comment: Merged company is called Indalo Therapeutics

COPYRIGHT 2016 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2016 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M & A Navigator
Date:Oct 19, 2016
Words:188
Previous Article:Dungarvin Acquires Indiana Home Healthcare Company.
Next Article:Deal snapshot: VAIL RESORTS CLOSES USD 1.056BN ACQUISITION OF CANADIAN MOUNTAIN RESORT OPERATOR WHISTLER BLACKCOMB.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters